Literature DB >> 31732150

Biochemical thresholds for pathological presentation of ATP synthase deficiencies.

Hana Nuskova1, Jana Mikesova2, Iuliia Efimova2, Alena Pecinova2, Petr Pecina2, Zdenek Drahota2, Josef Houstek2, Tomas Mracek3.   

Abstract

Mitochondrial ATP synthase is responsible for production of the majority of cellular ATP. Disorders of ATP synthase in humans can be caused by numerous mutations in both structural subunits and specific assembly factors. They are associated with variable pathogenicity and clinical phenotypes ranging from mild to the most severe mitochondrial diseases. To shed light on primary/pivotal functional consequences of ATP synthase deficiency, we explored human HEK 293 cells with a varying content of fully assembled ATP synthase, selectively downregulated to 15-80% of controls by the knockdown of F1 subunits γ, δ and ε. Examination of cellular respiration and glycolytic flux revealed that enhanced glycolysis compensates for insufficient mitochondrial ATP production while reduced dissipation of mitochondrial membrane potential leads to elevated ROS production. Both insufficient energy provision and increased oxidative stress contribute to the resulting pathological phenotype. The threshold for manifestation of the ATP synthase defect and subsequent metabolic remodelling equals to 10-30% of residual ATP synthase activity. The metabolic adaptations are not able to sustain proliferation in a galactose medium, although sufficient under glucose-rich conditions. As metabolic alterations occur when the content of ATP synthase drops below 30%, some milder ATP synthase defects may not necessarily manifest with a mitochondrial disease phenotype, as long as the threshold level is not exceeded.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATP synthase; Deficiency; Oxidative phosphorylation; Reactive oxygen species; Threshold effect

Year:  2019        PMID: 31732150     DOI: 10.1016/j.bbrc.2019.11.033

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  ATP synthase FOF1 structure, function, and structure-based drug design.

Authors:  Alexey V Vlasov; Stepan D Osipov; Nikolay A Bondarev; Vladimir N Uversky; Valentin I Borshchevskiy; Mikhail F Yanyushin; Ilya V Manukhov; Andrey V Rogachev; Anastasiia D Vlasova; Nikolay S Ilyinsky; Alexandr I Kuklin; Norbert A Dencher; Valentin I Gordeliy
Journal:  Cell Mol Life Sci       Date:  2022-03-06       Impact factor: 9.261

2.  Computational Design of Inhibitors Targeting the Catalytic β Subunit of Escherichia coli FOF1-ATP Synthase.

Authors:  Luis Pablo Avila-Barrientos; Luis Fernando Cofas-Vargas; Guillermin Agüero-Chapin; Enrique Hernández-García; Sergio Ruiz-Carmona; Norma A Valdez-Cruz; Mauricio Trujillo-Roldán; Joachim Weber; Yasser B Ruiz-Blanco; Xavier Barril; Enrique García-Hernández
Journal:  Antibiotics (Basel)       Date:  2022-04-22

3.  Current progress in the therapeutic options for mitochondrial disorders.

Authors:  E Koňaříková; A Marković; Z Korandová; J Houštěk; T Mráček
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

4.  Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat.

Authors:  Aleksandra Marković; Kateřina Tauchmannová; Miroslava Šimáková; Petr Mlejnek; Vilma Kaplanová; Petr Pecina; Alena Pecinová; František Papoušek; František Liška; Jan Šilhavý; Jana Mikešová; Jan Neckář; Josef Houštěk; Michal Pravenec; Tomáš Mráček
Journal:  Biomedicines       Date:  2022-01-26

5.  Sulforaphane Ameliorates Metabolic Changes Associated With Status Epilepticus in Immature Rats.

Authors:  Jan Daněk; Šárka Danačíková; David Kala; Jan Svoboda; Sonam Kapoor; Antonín Pošusta; Jaroslava Folbergrová; Kateřina Tauchmannová; Tomáš Mráček; Jakub Otáhal
Journal:  Front Cell Neurosci       Date:  2022-03-15       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.